<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214736">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290212</url>
  </required_header>
  <id_info>
    <org_study_id>REK V 77/2005</org_study_id>
    <nct_id>NCT00290212</nct_id>
  </id_info>
  <brief_title>Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause</brief_title>
  <official_title>Phase II Study of Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause: a Randomised Double Blind Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tromso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The International Osteoporosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <brief_summary>
    <textblock>
      Study Objective: To determine whether Natto supplementation in women immediately after
      menopause might prevent severe bone loss

      Study population: Women 50 - 60 years, 1-5 years after menopause

      Study Design: Double-blind, placebo-controlled, randomized controlled trial. A &quot;phase II&quot;
      clinical trial.

      Instruments Used to Measure Therapeutic Response: Lunar Prodigy DEXA bone densitometer

      Study Treatment Group: Daily supplementation with Vitamin K2, &quot;NATTO&quot;

      Study Control Group: Identically-looking placebo medication

      Duration of treatment: 12 months

      Duration of Subject Participation in Study: 12 months Assessment of Therapeutic response:
      Given an expected reduction of bone mass density of - 1.1% annually in the placebo group,
      the minimum clinically significant difference between the groups is 0.3 percentage points.
      The trial is therefore powered to detect a reduction in annual bone mass loss of 0.3
      percentage points in the treatment group.

      Numbers of Evaluable Subjects Required: 304 Maximum # Subjects 334
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mass density</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Perimenopausal Bone Loss</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natto capsules (food suppl.) cont. 360 microg. vit K2/day</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women living in the city of Tromsø, not using hormone replacement therapy, 1-5 years
             after menopause.

        Exclusion Criteria:

          -  History of hip fracture

          -  Bone disease affecting bone mineral density

          -  Use of vitamin K antagonists

          -  Significant co-morbidity that makes it difficult to obtain BMD measurements

          -  Use of hormone replacement therapy or other therapy that influence bone remodeling
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Emaus, MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NAFKAM, Fac.of Medicine, Univ. of Tromsø, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sameline Grimsgaard, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinjar Fønnebø, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NAFKAM, University of Tromsø, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>NO 5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center, University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>N-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <lastchanged_date>January 23, 2008</lastchanged_date>
  <firstreceived_date>February 9, 2006</firstreceived_date>
  <keyword>Women</keyword>
  <keyword>Bone density</keyword>
  <keyword>Menopause</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Vitamin K2</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
